Latest Breaking News On - ரொபெர்டோ பெலினி - Page 1 : comparemela.com

BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights

BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 – – Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 – BELLUS Health Inc. a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic … – Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 – – Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 –

BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference

2 TSX Stocks That Could Return 100% in 2021

Image source: Getty Images The 2020 global pandemic hurt many businesses across various industries. Many companies operating in travel and tourism-related, arts and entertainment, restaurant, and accommodation sectors suffered the most. Some of the operations might not return to pre-corona levels and eventually shut down. Meanwhile, the health and wellness industry is evolving rapidly, precipitated mainly by COVID-19. New treatment drugs, world-class research, product diversity, and supply-chain advancements are becoming increasingly important. On the TSX, two stocks are flying under the radar. Their growth potentials should be tremendous in 2021, barring hitches in their respective programs or business strategies. Critical treatment for chronic ailments

The top reads of the year from Report on Business magazine

Opinion: What Canada needs to do to build a world-class biotech sector